KOL Identification

A multinational pharmaceutical and diagnostics company was interested in learning more about the U.S. market opportunity for their novel noninvasive prenatal test in development

A global healthcare investment firm wanted to perform a commercial due diligence (CDD) prior to investment in a company producing a novel handheld diagnostic

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A leader in research tools and clinical diagnostic development asked DeciBio to evaluate the opportunity for an ultra-sensitive detection platform in methylation analysis

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform